Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only by Lofstad, G Elisabeth et al.
Acta Pædiatrica ISSN 0803–5253
REGULAR ARTICLE
Cognitive outcome in children and adolescents treated for acute
lymphoblastic leukaemia with chemotherapy only
G Elisabeth Lofstad (Elisabeth.Lofstad@svt.ntnu.no)1, Trude Reinfjell2, Knut Hestad3, Trond H Diseth4
1.Neuropsychological Clinic, Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway
2.Regional Centre for Child and Adolescent mental health, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
3.Neuropsychological Clinic, Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway
4.Section for Child and Adolescent Psychiatry, Paediatric Clinic, Rikshospitalet, University Hospital, Oslo, Norway
Keywords
Acute lymphoblastic leukaemia, Chemotherapy,
Children, Cognitive functioning
Correspondence
G. Elisabeth Lofstad, clinical neuropsychologist,
Department of Psychology, the Norwegian
University of Science and Technology (NTNU),
N-7491, Trondheim, Norway.
Tel: +47 73590992 |
Email: Elisabeth.Lofstad@svt.ntnu.no
Received
10 March 2008; revised 26 August 2008;
accepted 4 September 2008.
Re-use of this article is permitted in accordance
with the Creative Commons Deed, Attribution 2.5,
which does not permit commercial exploitation.
DOI:10.1111/j.1651-2227.2008.01055.x
Abstract
Objective: To examine cognitive outcome in children and adolescents with acute lymphoblastic
leukaemia (ALL) in remission, treated with central nervous system prophylactic chemotherapy only.
Method: Thirty-ﬁve children and adolescents, age 8.4–15.3 years in long-term remission from ALL,
4.2–12.4 years post diagnosis, without relapse and no prediagnosis history of neurodevelopmental
disorder were compared with 35 healthy controls matched for gender and age, on measures of
intellectual functioning Wechsler Intelligence Scale for Children-Third Edition (WISC-III).
Results: All but two of the ALL survivors treated by chemotherapy only obtained WISC-III Total
Intelligence Quotient (IQ) scores in the normal range (M = 95.3), but their scores were signiﬁcantly
below levels for their matched controls and below normative standards for WISC-III. The difference
between patients and controls was signiﬁcant at the p < 0.001 level for the following measures:
Total IQ, Verbal IQ, Verbal Comprehension Index, Freedom from Distraction Index and three verbal
subtest scores.
Conclusion: The results indicate long-term sequelae in global cognitive functions, and indicate that verbal
function, processing speed, attention and complex visual-spatial problem solving may be affected in the
chemotherapy only group.
INTRODUCTION
Acute Lymphoblastic Leukaemia (ALL) is the most com-
mon childhood malignancy, accounting for about 75% of
all leukaemias and 25% of childhood cancers, with an in-
cidence of 3.9/100.000 and a peak incidence at the age of
3–4 years (1). This is a disease of the lymphoid cells, where
malignant white blood cells migrate via the circulatory sys-
tem to virtually all organ systems, including the central
nervous system, where the blood-brain barrier creates a
sanctuary for cancer cells.
Current treatment commonly lasts for 24–30 months. All
protocols include central nervous system prophylactic treat-
ment to prevent central nervous system relapse. Treatment is
based on complex multi-agent combinations of chemother-
apies; the intensity of the therapy is determined according to
risk groups, defined by graded risk for relapse and long-term
sequelae. Some very high-risk cases also involve the use of
cranial radiation therapy (CRT).
Treatment protocols are frequently changed in order
to maximize long-term event-free survival and minimize
long-term sequelae. Research on neurocognitive long-term
outcome is closely interwoven with the ongoing treatment
refinements.Theintroductionofcentralnervoussystem pro-
phylactic CRT was followed by an increase in the five-year
event-free survival rate from below 20% in 1960 to about
75–85% today (2). Unfortunately, CRT was documented as
being significantly related to neurotoxicity with neurocogni-
tive and neurobehavioral long-term sequelae, with younger
children and particularly young girls particularly vulnerable
(3,4). Through advances in central nervous system-directed
chemotherapy, the use of CRT has been gradually replaced
by intensified chemotherapy. In the Nordic countries, more
than 90% are now treated with chemotherapy only (1).
Recent chemotherapy only protocols often employ simul-
taneous administration of different groups of drugs, com-
monly including nucleoside analogs, glucocorticoids and
antifolates, all of which are suspected of causing delayed
neurotoxicity (5).
The cognitive functioning in long-term survivors of child-
hood ALL treated by chemotherapy only protocols has been
evaluated by comparison to differentgroups, but results have
been inconclusive. Earlier studies that focused on treatment
effects often reported fewer and only subtle deficits in the
chemotherapy only groups as compared to survivors treated
with CRT (6,7), while other studies have reported no signif-
icant cognitive differences between such groups (8). Studies
that have focused on both treatment and illness factors by
including multiple samples (CRT treatment, chemotherapy
only treatment, other illnesses such as non-central nervous
system cancer, asthma and healthy controls) have shown a
gradual effect on cognitive functions. ALL survivors treated
with CRT showed the lowest cognitive levels, followed
by chemotherapy only groups. Patients treated for other
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non-central nervous system cancers or asthma had higher
scores than the chemotherapy only group, but scored below
healthy controls (9,10). Gender and age at diagnosis have
been documented to be significant moderators on cognitive
functions (10), in studies by Brown et al. (11) only gender
acted as a significant moderator.In a review by Moleski (12);
all studies where cognitive function in survivor groups was
compared to matched healthy controls reported significantly
lower scores in survivor groups.
The lower scores on the WISC as documented in the liter-
ature might reflect impairment of both global and/or specific
neurocognitive abilities. Studies that focused on outcomes
for specific cognitive functions have reported significant im-
pairment in Verbal IQ, Performance IQ, attention, infor-
mation processing, executive functions, psychomotor skills,
as well as verbal visual memory (13) and learning difficul-
ties (14,15). Specific impairment in non-verbal function and
freedom from distractibility has been documented (11), but
specific impairment of Verbal IQ has also been documented
(7).
The aim of this study was to explore cognitive out-
comes in long-term survivors of childhood ALL treated with
chemotherapy only in accordance with protocols developed
in 1992 by the Nordic Society of Pediatric Hematology
Oncology-ALL (NOPHO-1992), which is used in Denmark,
Finland, Iceland, Sweden and Norway. The hypothesis is
that survivors of childhood ALL treated with chemotherapy
only protocols will have decreased level in cognitive func-
tioning compared to healthy controls and test normative
standards.
MATERIALS AND METHODS
The present study consists of 35 children and adolescent
long-term survivors of childhood ALL and 35 healthy con-
trols matched for age, gender and socio-demographic vari-
ables (Table 1). The children and adolescents in the ALL
survivor group were recruited from Rikshospitalet Univer-
sity Hospital in Oslo and St. Olav’s University Hospital in
Trondheim, Norway. The treatments were initiated from
May 1992 through 1999 according to NOPHO-ALL 1992
protocols, with patients grouped as standard risk, interme-
diate risk, high-risk 1 group age below five years and high-
risk 2 group age above five years. The very high-risk group
was excluded. Patients were included if they met the follow-
ing criteria: four years or more post-diagnosis, in continuous
remission since the initial treatment with no relapses, com-
pletion of one single course of treatment without CRT. To
maximize the homogeneity in the sample and minimize con-
founding effects of condition with a documented effect on
cognition, patients in the very high-risk group treated with
CRT or bone-marrow transplantation and patient with hos-
pital record of central nervous system or B-cell leukaemia
or other neurodevelopmental syndrome or diseases were not
included. To prevent any culture or language bias in the test
results, children from families from non-Nordic cultures and
whose first language was not a Nordic language were not in-
cluded. Fifty-one children and adolescents from the patient
Table 1 Sociodemographic characteristics and treatment variables in 35 chil-
dren treated for ALL and 35 healthy controls
ALL Healthy
Gender
Girl: n (%) 18 (51.4) 18 (51.4)
Age at study in years
Mean (SD) 11.5 (1.9) 11.6 (1.9)
Range 8.4–15.3 8.8–15.1
Family composition; n (%)
Both parents 26 (74.3) 26 (74.3)
Parent with partner 3 (8.6) 4 (11.4)
Parent single 4 (11.4) 5 (14.3)
Unknown, not reported 2 (5.7) 0
Parent: age in year, mean (range)
Mother 39.6 (30–54) 40.1 (30–52)
Father 43.1 (32–58) 43.0 (30–59)
Parent: education in years, mean (range)
Mother 13.8 (10–19) 14.0 (9–19)
Father 14.3 (10–20) 13.7 (10–19)
Economy self evaluation
Very good; n (%) 3 (8.6) 5 (14.3)
Good; n (%) 21 (60.0) 13 (37.1)
Average; n (%) 9 (25.7) 17 (48.6)
Poor 2 (5.7) 0
Home
Own house, n (%) 33 (94.3) 34 (97.4)
Community
Urban, n (%) 12 (34.3) 16 (45.7)
Rural, n (%) 23 (65.7) 19 (54.3)
Diagnosis and treatment
Age at diagnosis in years
Mean (SD) 3.8 (1.6)
Median 3.6
Range 1.6–7.5
Time since diagnosis in years
Mean (SD) 7.7 (1.9)
Median 7.8
Range 4.2–12.4
Treatment protocols, n (%)
Standard risk 14 (40.0)
Intermediate risk 15 (42.9)
High risk 1 4 (11.4)
High risk 2 2 (5.7)
No signiﬁcantly differences were seen between the two groups.
pools provided by the two hospitals met the inclusion crite-
ria. Of 51 patients and their parents contacted by mail, 35
children (69%), 18 girls and 17 boys, agreed to participate in
this study. This group had a mean age of 11.5 years (range
8.4–15.3 years) and was 4.2–12.4 years postdiagnosis. The
16 children who did not participate (13 girls and 3 boys)
reported difficulty in finding time for the two-day testing
period, whilst other families declined because they did not
want to remind their children of their cancer treatment.
The physically healthy children and adolescents in the
comparison group were recruited from four public schools
and matched by gender and age. The schools were selected
to match demographics. As in the patient group only pupils
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Table 2 Independent sample t-test on cognitive outcome in 35 ALL survivors and 35 matched healthy control (HC) and one sample t-test for the ALL group
compared to the Swedish WISC-III test norms
ALL n = 35 HC n = 3 5 A L Lv s .H C A L Lv s .n o r md a t a
Inc Mean (SD) Mean (SD) t-score p-value Dif. 1 t-score p-value Dif. 2
IQ
T IQ 95.3 (15.9) 109.4 (12.9) −4.06 <0.001 14.1 −1.74 0.091 4.7
V IQ 94.1 (15.0) 110.1 (11.8) −4.92 <0.001 15.9 −2.30 0.027 5.9
P IQ 97.9 (16.0) 106.4 (13.7) −2.41 0.019 8.6 −0.79 0.434 2.1
Index
VCI 94.7 (15.6) 108.6 (12.4) −4.12 <0.001 13.9 −2.01 0.053 5.3
POI 99.4 (17.7) 106.7 (12.6) −1.98 0.052 7.3 −0.19 0.850 0.6
FDI 94.4 (15.0) 108.8 (15.6) −3.95 <0.001 14.4 −2.23 0.033 5.6
PSI 88.8 (14.9) 97.9 (15.6) −2.49 0.015 9.09 −4.45 <0.001 11.2
Subtests
Inf tvc 10.1 (2.8) 11.0 (2.5) −1.33 0.187 0.9 0.24 0.814 −0.1
Sim tvc 8.7 (3.2) 11.6 (2.6) −4.20 <.001 2.9 −2.51 0.017 1.3
Voc tvc 8.1 (3.1) 10.4 (2.5) −3.46 0.001 2.3 −3.65 0.001 1.9
Com tvc 9.7 (3.3) 12.8 (2.5) −4.53 <0.001 3.2 −0.62 .540 0.3
Ari tvd 9.0 (2.5) 11.6 (3.0) −3.97 <0.001 2.6 −2.38 0.023 1.0
DS d 9.5 (3.2) 11.1 (3.5) −1.94 0.057 1.5 −0.90 0.375 0.5
PC tpo 9.9 (3.1) 9.6 (2.8) −0.32 0.747 0.2 −0.27 0.789 0.1
PA tpo 10.3 (3.2) 11.5 (2.9) −1.58 0.119 1.1 0.59 0.559 −0.3
BD tpo 9.6 (3.0) 11.7 (2.4) −3.30 0.002 2.1 −0.78 0.437 0.4
OA tpo 9.7 (3.9) 11.3 (2.1) −2.45 0.028 1.7 −0.52 0.609 0.3
Cod tps 9.1 (2.8) 10.4 (2.5) −1.98 0.051 1.3 −1.89 .067 0.9
SS s 7.1 (3.5) 8.9 (3.6) −2.21 0.031 1.9 −4.93 <0.001 2.9
Maz 10.0 (4.2) 10.0 (3.8) −0.03 0.976 0.0 −0.41 0.968 0.0
Raw
DSf 8.03 (1.74) 8.92 (2.13) −0.98 0.052 0.89
DSb 5.19 (2.09) 5.70 (2.21) −1.03 0.308 0.51
Dif. 1: Group differences in mean scores for ALL survivors versus healthy controls (HC).
Dif. 2: Group differences in mean scores ALL compared to test normative means, ALL norm data; One sample t-test between ALL survivor group and the WISC-III
normative mean.
Inc: This column shows the relation between subtests and the composite scores, each composite is marked by one letter: t: TIQ, Total IQ; v: VIQ, Verbal IQ; p: PIQ,
Performance IQ; c: VCI, Verbal Comprehensions Index; o: POI, Perceptual Organization Index; d: FDI, Freedom from Distractibility Index; s: PSI, Processing Speed
Index.
Subtests: Inf, Information; Sim, Similarity; Voc, Vocabulary; Com, Comprehension; Ari, Arithmetic; DS, Digit Span; PC, Picture Completion; PA, Picture Arrangement;
BD, Block Design; OA, Object Assembly; Cod, Coding; SS, Symbol Search; Maz, Mazes; DSf, Digit Span forward and DSb, Digit Span backward.
Raw: in raw scores.
from Nordic families with a Nordic first language with-
out any known neurodevelopmental syndrome or disor-
ders were recruited. The participation rate was 79%, with
a mean age of 11.6 years and a range of 8.8 years to
15.1 years.
Methods
Cognitive function was measured with the Wechsler Intelli-
gence Scale for Children-Third Edition (WISC-III) Swedish
version with Norwegian translation (16,17). All 13 sub-
tests were administered: Information, Similarity, Vocabu-
lary, Comprehension, Arithmetic, Digit Span, Picture Com-
pletion, Picture Arrangement, Block Design, Object Assem-
bly, Coding, Symbol Search and Mazes. The Digit Span
raw score was divided into a forward test of memory span
and backward test of working memory. Age-adjusted scores
for specific subtests were summarized and transformed into
three intelligence scales; Total IQ, Verbal IQ and Per-
formance IQ, and four composites index quotients; Ver-
bal Comprehension Index, Perceptual Organization Index,
Freedom from Distractibility Index and Processing Speed
Index (Table 2).
The parents were asked to fill in a standardized question-
naire regarding case history and demographic data based on
a revised parental interview (18).
Procedure
The study was approved by the Regional Ethics Committee
of Medical Research. Written permission to contact the par-
ents of children treated for ALL in their patient pools was
provided by the leaders of the Paediatric Clinics at Rikshos-
pitalet and St. Olav’s Hospital. Written information about
the project, parental and patient (adolescent) consent forms,
andself-addressed,stampedenvelopesweresentbyordinary
mail to parents of children who met our inclusion criteria
(n = 51). If forms were not returned within three weeks,
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parents were contacted by phone. All children for whom
parents had provided informed consent were examined in a
quiet room at the hospital where they had been treated for
ALL.
To assemble the control group, the county borough coun-
cils for schools in one urban and one rural county were
contacted to discuss the demographics of different schools,
and to obtain permission to contact school headmasters in
theirrespectivecounties.Whentheappropriateofficialspro-
vided written informed consent, four school headmasters
were contacted to provide informed consent, which was
provided. Two Trondheim city headmasters (one from an
elementary school, and one from a junior high school) were
contacted first and asked to create a sample of two girls and
two boys in each age group by drowing lots from gender-
and age-specific (according to school year) pupil lists. The
participants from these two schools and the children from
the ALL group were divided by gender, ranged by age in
months and matched by age. The age in months for ALL
survivors without healthy matches was then recorded, after
whichheadmastersfromtheruralcountyofNord-Trøndelag
were asked to select healthy matches by gender and age in
months. Headmasters sent written information and consent
forms to selected families, who were subsequently contacted
by phone.Headmasters were instructednot toinclude pupils
with known neurodevelopmental diseases diagnosed by the
specialist health services. When informed consent was given
by parents and adolescents, the WISC-III was administered
in a quiet room at their respective schools. All tests were
administered by the same individual, who is an experienced
psychologist (T. R.).
STATISTICS
The match between the two groups was evaluated by com-
paring demographical variables with independent sample
t-tests or Pearson’s chi-square. Cognitive outcomes for chil-
dren and adolescents treated for ALL were compared to
children and adolescents in the healthy control group by
use of an independent sample t-test, and to mean scores
from the WISC-III test norms using a one sample t-test. The
interrelation between each of the global cognitive scores
and the interrelation between the global cognitive scores
and the subtest scores were explored by Pearson’s correla-
tion test. All results were evaluated using two-tailed analy-
ses. The data were analysed using the Statistical Package for




The demographical variables revealed no significant differ-
ences between patients and healthy controls (Table 1).
Cognitive outcome
All but two of the ALL survivors obtained WISC-III Total
IQ scores in the normal range (M = 95.3, Table 2). The
ALL group scored significantly below the normative mean
on the Verbal IQ, the Processing Speed– and Freedom from
Distractibility-Indexes and the Symbol Search, Vocabulary,
Similarity and Arithmetic subtests.
The between-group comparisons revealed significantly
lower scores for the ALL group on six of the seven global
measurements (Table 2). Verbal IQ, Total IQ, Verbal Com-
prehension Index and Freedom from Distractibility Index in
the survivor group were 13 IQ points or more below healthy
controls at the p < 0.001 level, while 7 of the 13 subtest
scores were significantly below (p < 0.05) healthy controls.
The group differences in the subtest scores were most strik-
ing with regards to Comprehension, Similarity and Arith-
metic (p < 0.001).
There was a high correlation for the five most global com-
posite scores; Total IQ, Verbal IQ, Performance IQ, Verbal
Comprehension Index and Perceptual Organization Index
in both groups (r = 0.63 to 0.98 in the survivor group, r =
0.50tor=0.97inthecontrolgroup).TheFreedomfromDis-
tractibility Index was significantly correlated to these other
scores in the ALL survivor group (p < 0.01). In the healthy
group Freedom from Distractibility Index was significantly
correlated to Total IQ, Verbal IQ and Performance IQ at the
p < 0.05 level. This between group difference was only seen
in one subtest the Digit Span, which was significantly corre-
lated to global measures in the ALL survivor group but not
in the healthy group. Arithmetic (the other subtest in Free-
dom from Distractibility Index) was significantly correlated
to the five global measures in both groups. Processing Speed
Index was not significantly correlated with the global scores
in the ALL group, but it was significantly correlated to all
five global measures in the healthy group (Total IQ, Verbal
IQ, Performance IQ and Perceptual Organization Index at
p < 0.01, and Verbal Comprehension Index at p < 0.05
level). This pattern in between group difference was found
in both subtests (Coding and Symbol Search).
DISCUSSION
The present study indicates that children and adolescents
treated for ALL early in life by chemotherapy only show
decreased global neurocognitive functioning. Their achieve-
ments on Total IQ, Verbal IQ, Verbal Comprehension Index
and Freedom from Distractibility Index were all approxi-
mately 1 standard deviation below the matched controls.
Group comparisons of the profiles from the WISC-III sub-
tests scores indicate decreased level in verbal functioning,
complex problem solving for arithmetic and visual spatial
tasks, attention and processing speed. The majority of the
reduced subtests are characterized by heavier reliance on
higher mental or frontal lobe functions, which may rep-
resent a shared factor. Processing speed was also signifi-
cantly lower in the ALL group, but their Processing Speed
Index scores were not significantly related to their scores
on the other global measures. The ALL survivors’ cognitive
functions were also significantly below the test normative
data for Verbal IQ, Processing Speed Index, Freedom from
Distractibility Index and four subtests.
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The results of the present study correspond to earlier
documentation. In the review by Moleski (12) most stud-
ies documented cognitive outcome within normal range;
but all studies enlisting sibling controls found decline in
intellectual, neuropsychological, or academic achievement;
the mean IQ value for healthy siblings of ALL patients
was approximately 112–113. Previous studies including
healthy controls are rare and the chemotherapy only pa-
tient groups have often been small, but the trend seems
rather consistent. Among six studies reported over the last
decade (7,9,13,15,19,20), four have reported a lower group
mean Total IQ in ALL survivors of 8.3 to 22.2 IQ points
compared to matched healthy controls (9,13,15,20). One
study with only girls reported a lower group mean of 6.6
(19) in the survivor group, while another study reported
4.5 points lower Total IQ in the survivor group (7), al-
though the healthy control group appeared to be some-
thing between a matched group and a larger test norma-
tive group. Five of these studies reported Total IQs from
97.6 to 107.2 among the ALL survivor groups (7,9,15,19,20),
but all the control groups scored above Total IQ = 110.
The largest group difference was reported in the study
with the lowest Total IQ in the healthy group (Total IQ
= 104) (13). In a study including 132 ALL survivors treated
by chemotherapy only, Von Der Weid et al. (10) reported
significant effects of gender and age at diagnosis among the
survivor group. The whole group scored at the same level as
patients treated for solid tumours (where the treatment did
not include central nervous system prophylaxis treatment).
The ALL survivors with the best cognitive prognoses (boys
or age at diagnosis above six years) obtained a Total IQ close
to 110, or nearly 10 IQ points above the ALL survivors with
poorer cognitive prognoses.
In our study the group differences of specific cognitive
functions was most striking and consistent for verbal func-
tion (Verbal IQ) and attention (Freedom from Distractibility
Index).Specific decreases in verbalfunctionshave beendoc-
umented previously by Kingma et al (7). The ALL survivors
in their study performed significantly below a large Dutch
normative group on Verbal IQ, but no other scores showed
significant differences. However, these researchers reported
the cognitive functioning from two groups of ALL survivors
treated by two different chemotherapy only protocols, and
found this effect in only in one of the chemotherapy treat-
ment groups. This finding of specific deficits in verbal func-
tion contrasts to findings from Brown (11), who reported
specific deficits in non-verbal tasks and attention (Freedom
from Distractibility Index). Data from the present study in-
dicate deficits in complex visual spatial problem solving as
measured by Block Design and Object Assembly, but not
in the less abstract Picture Completion and Picture Assem-
bly subtests, which load highly for detail recognition. The
ALL survivors in this study did not differ significantly from
controls for rote memory of learned facts, recognition and
field-dependent visual tasks. Other researchers have docu-
mented mild but consistent impairment in recall of visual fig-
ures, verbal stories and memory span (13). Attention deficit
has also been documented (11,21), and in research on CRT
groups it has been postulated as a possible core deficit that
results inlater generalizedcognitiveandlearningdeficits(6).
The lower Freedom from Distractibility Index scores in our
ALL survivor group were largely caused by poorer scores
on the Arithmetic subtest, which may be highly related to
global cognition. Impaired processing speed has been doc-
umented by Mennes et al. (22). In our study, ALL patients
had significantly lower Processing Speed Index scores than
normative test data and that of controls, indicating impair-
ment in processing speed, but Processing Speed Index was
not significantly correlated to the other global score, which
suggests it may be a specific deficit. Possible specific deficits
in other functions may be confounded by global cognitive
deficits.
Documentation of delayed brain changes, most com-
monly in reduction in the white matter volume, calcification,
changes in glucose utilization and abnormalities in event-
related potential (ERP) (5,21,23), strengthen our hypothe-
sis of decreased levels in cognitive functioning. The young
brain undergoes rapid development with a large increase in
white matter volume, particularly in the frontal lobe, but
also in the right hemisphere and the brain network. Imma-
ture white matter in areas undergoing rapid development
is thought to be especially vulnerable. These areas are also
known to be important in complex neurocognitive function-
ing. The association between documented neurological se-
quelae and neurocognitive impairment is still unclear. Some
researchers reported no correlation (24), while other studies
reported significant correlation (21,23).
The mean IQ in the control group in the present study
might seem high compared to normative standards, but cor-
responds to previous documentation of cognitive level in
matched control group of healthy children. The girl: boy ra-
tio at 13: 3 among the survivors who refused to participate, is
unlikely to have occurred by chance. The test leader was not
blinded to the subject’s group connection; the ALL group
was tested in their respective hospitals, while the healthy
children were tested at their respective schools and the num-
ber of participants was relatively low. Altogether these fac-
tors may limit our ability to document smaller impairments,
and to make generalizations from our results.
Nevertheless, this study does have significant strengths,
comprised of the close match to the healthy control group
for gender, age and socio-economic variables, the homo-
geneity of the groups, the inclusion of 69% of the cohort
treated for childhood ALL in the two hospitals following
the inclusion criteria, and the fact that all participants were
tested by the same test leader who was an experienced clin-
ical psychologist.
CONCLUSIONS
The present data strongly supports the hypothesis that early
childhood ALL treated by chemotherapy only influences
subsequent brain development and is followed by cognitive
sequelae. Even though the cognitive outcome is in the nor-
mal range, it represents a substantial decrease of as much
as one standard deviation compared to matched healthy
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controls. Our study revealed decreases in attention, verbal
function, complex visual spatial problem solving and
processing speed. The data do not allow us to draw con-
clusions on possible function-specific deficits. The WISC-
III subtests are constructed to show both global intelli-
gence and specific function; as a result, subtest scores may
be confounded by global cognition. Strong correlations be-
tween the subtest scores and the composite scores in the
present study may indicate that the survivors’ lower subtest
scores may be influenced by a lower level of global cogni-
tive function. Only Processing Speed was not significantly
related to other scores. Further conclusions on the effect of
function-specific deficits require additional function-specific
neuropsychological tests. The growing number of reports of
group mean Total IQ scores above 110 obtained by siblings
and other healthy matched groups and patient groups with
good cognitive prognosis highlights the importance of not
merely relying on normative data for evaluating cognitive
outcome.
The accumulated data showing cognitive sequelae after
childhood ALL treated with chemotherapy only must be
taken into account by schools and health care providers.
Reduced IQ is a well-known risk factor for mental health
problems, psychosocial dysfunction and school problems.
Intervention programs must be constructed for long-term
follow up to limit the secondary effects of lower IQ. ALL
survivors should be taught strategies to compensate for their
deficits.
In forthcoming publications we will focus further on out-
comes in specific areas of neurocognitive functions evalu-
ated by neuropsychological tests and the effect of risk factors
for cognitive sequelae identified for treatment with CRT.
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